SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected fourth-quarter outlook, citing softer PC demand, higher memory costs and supply constraints, has overshadowed stronger data-center growth and a quarterly earnings beat. Traders are debating whether the sharp selloff reflects real operating concerns or an overreaction.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook sparked a selloff as investors focused on sharply higher AI infrastructure spending, negative free cash flow, and softer-than-expected revenue and guidance. Traders are divided: some see the spending as a risk to returns, while others argue that accelerating AWS growth supports the investment.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits post-earnings selloff is tied to a softer fourth-quarter outlook, declining search referrals and weaker U.S. user trends, alongside plans to test requiring logins to access content. Traders debate whether the drop overstates the risk given strong quarterly results or reflects genuine concerns that traffic losses and the login change could hurt user growth and monetization.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Updated lifileucel lung-cancer data sparked a sharp selloff: the overall response rate was broadly unchanged, while a retrospective biomarker-selected subgroup showed a much higher response rate and needs prospective validation. Traders are split between viewing the subgroup and planned filing path as promising and worrying about durability, regulatory uncertainty, and managements confusing presentation.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention amid weakness in mega-cap tech, with traders focused on Alphabets earnings-related selloff and concerns about slowing Search growth, AI monetization and heavy investment spending. Some see the pressure as evidence of an AI-fueled bubble and expect further downside, while others view it as a pullback in major tech leaders rather than a lasting break in the long-term story.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabets quarterly results sparked a record selloff as traders focused on softer Search and advertising performance and heavy AI investment that pressured free cash flow, despite strong Cloud growth. The community is split between concern that spending and AI-driven changes to Search could weigh on cash generation and ad economics, and dip buyers pointing to Cloud momentum and Alphabets longer-term AI prospects.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNows post-earnings selloff is centered on a softer outlook for contracted-revenue growth and a slight earnings miss, despite continued revenue growth and a higher AI target. Traders are debating whether the reaction reflects justified concern about slowing growth, valuation and AIs impact on software, or an overreaction that could create a buying opportunity.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

A sharp selloff in silver and SLV, with repeated new lows and key support under pressure, dominates the discussion. Traders debate rate and yield concerns versus an oversold dip-buying opportunity, while some attribute the decline to alleged paper-market manipulation.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Reports of a major Binance security breach are driving discussion, with traders linking the incident to crypto-wide selling and Bitcoins drop toward support levels. The community is split between concerns about exchange security and further downside, and dip-buyers who argue the exchangenot Bitcoin itselfwas compromised.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians Q3 results beat expectations and the company raised its delivery outlook as the R2 production ramp progresses. Bulls view this as improving execution, while skeptics question the muted share reaction and continued cash burn.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek 2026 Annual Meeting

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced it will present two presentations at the upcoming ObesityWeek 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C. The first late-breaking oral presentation will feature topline results from...

Amylyx Pharma Q2 2026 Earnings Call Transcript

Amylyx Pharma (NASDAQ:AMLX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This transcript is brought to you by Benzinga APIs. For real-time access to ourread more...

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET. A live webcast of the presentation can be...

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will present at the 24th Annual Morgan Stanley Global Healthcare Conference. The fireside chat will take place on Tuesday, September 15th, 2026, at 12:20 p.m. ET. A live webcast of the presentation...

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Key PointsAnalysts also raised their price targets on the company...

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? 

Equity

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence. 


Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to...

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus

The U.S. 30-year Treasury yield climbed to a fresh 19-year high on Tuesday, trading at 5.274% at the time of writing, while the 10-year Treasury yield was at 4.692%.

Why Did AMLX, IOVA, OKE Stocks Hit 52-Week Highs Today? 

Investors responded to clinical progress, improving commercial performance and new growth opportunities.


Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Iovance Biotherapeutics hit a 52-week high as UBS lifted its price target.&nbsp;</li><li>Amylyx Pharmaceuticals hit a three-year high after pricing a $500 million stock offering to fund potential commercialization.&nbsp;</li><li>Morgan Stanley raised ConocoPhillips’ price target to $151 with an ‘Overweight’ rating.</li></ul>Iovance Biotherapeutics (IOVA), Amylyx Pharmaceuticals (AMLX) and ConocoPhillips (COP) stocks each reached fresh 52-week highs on Thursday as operating milestones and favorable analyst calls improved investor confidence.&nbsp;Iovance Biotherapeutics stock surged 12%, while Amylyx Pharmaceuticals and ConocoPhillips stocks gained over 2% and 3%, respectively.&nbsp;<h2 class="st-heading-2">UBS Raises Iovance Price Target&nbsp;</h2><a href="https://stocktwits.com/symbol/IOVA">Iovance Biotherapeutics stock</a> hit an annual high of $9.36 as strong second-quarter performance and bullish analyst updates fueled its recent rally. The company reported $99.3 million in fiscal second-quarter (Q2) product revenue, including $91 million in U.S. Amtagvi sales, up 52% from the previous quarter. Gross margin also improved to 56%, helped by better manufacturing efficiency and faster treatment turnaround times.&nbsp;Wall Street analysts added to the positive sentiment. On Thursday, UBS raised its price target to $7 while maintaining a ‘Neutral’ rating, citing better performance at treatment centers and improved manufacturing. Iovance expects to have 110 active authorized treatment centers by year-end, while investors are also watching for SARATOGA trial results expected in late October.On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory.&nbsp;<h2 class="st-heading-2">$500M Offering Adds Firepower To Amylyx’s Growth Plans&nbsp;</h2><a href="https://stocktwits.com/symbol/AMLX">Amylyx Pharmaceuticals stock</a> surged to a three-year high of $40.44 on continued momentum of strong Phase 3 results for its experimental drug avexitide and a major new capital raise.&nbsp;On Tuesday, the company said its LUCIDITY Phase 3 trial met its main goal in treating post-bariatric hypoglycemia (PBH). Avexitide reduced the combined rate of severe hypoglycemic events by 55% versus placebo and met secondary goals. Amylyx plans to submit the drug for FDA approval by the end of 2026. Riding the positive clinical news, Amylyx priced an upsized $500 million stock offering at $35.50 per share. The financing gives the company capital to prepare for a potential commercial launch while reducing its reliance on debt.&nbsp;Retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Morgan Stanley Sees More Upside For ConocoPhillips&nbsp;</h2><a href="https://stocktwits.com/symbol/COP">ConocoPhillips stock</a> hit a three-year high of $135.87 as investors continued to respond to strong second-quarter results, higher production and positive analyst calls. Earlier this month, the oil and gas company reported adjusted earnings of $3.24 per share, beating Wall Street's $2.85 estimate. Production also reached 2.248 million barrels of oil equivalent per day, exceeding the top end of its guidance.&nbsp;Morgan Stanley raised its price target to $151 with an ‘Overweight’ rating, implying a 12% upside to the stock’s last close. Analyst Devin McDermott noted that, unlike pure-play refiners, integrated energy companies have not benefited as much from stronger refining margins, leaving room for their shares to catch up.Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;So far this year, COP, AMLX and IOVA stocks have surged between 44% and 229%Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wmt-vs-tgt-walmart-has-the-scale-target-has-turnaround-momentum-which-retail-stock-looks-better-now/cZYBiRVRJZC">WMT Vs TGT: Walmart Has The Scale, Target Has Turnaround Momentum — Which Retail Stock Looks Better Now?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?

Conoco Phillips

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$28.68
Prev Close	$28.07
Open	$28.13
Dividend Yield	0.00%
50-Day Moving Average	$31.11
Beta	1.77
Avg. Volume	1.49M
PE Ratio	-20.02

52-Week High	$41.14
52-Week Low	$10.83
Market Capitalization	$3.52B
EPS (Annual)	-$1.53
Price to Book	13.35
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMLX Fundamentals